Covaxin can be back-up if Serum Covishield s efficacy is in doubt: AIIMS Director
Calling it a great day for the country, AIIMS Director Dr Randeep Guleria said that initially Serum-AstraZeneca s Covishield will be administered to the people
BusinessToday.In | January 4, 2021 | Updated 00:18 IST
India has finally approved two vaccines to protect the population against coronavirus. The Drug Controller General of India (DCGI) has approved Bharat Biotech s Covaxin and Serum-AstraZeneca s Covishield for emergency use in the country.
Following the development, Dr Randeep Guleria, the Director of All India Institute of Medical Sciences (AIIMS) in Delhi, laid out the plans how the two inoculations could be used to vaccinate Indians. Exclaiming that it is a great day for the country, he said that initially Covishield will be administered to the public. Later, as Covaxin becomes available, it can be treated as a back-up.
URL copied Image Source : PTI
Hyderabad: Prime Minister Narendra Modi being briefed during a visit to the Bharat Biotech facility to review the development of indigenous COVID-19 vaccine candidate Covaxin, on the outskirts of Hyderabad, Saturday, Nov. 28, 2020.
India s drugs regulator on Sunday gave its nod to Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country. The World Health Organisation (WHO) welcomed the move, saying it will help intensify and strengthen the fight against the pandemic in the region .
Earlier on Saturday, a dry run for coronavirus vaccination was conducted by all states and union territory administrations to test the linkages between planning and implementation and to identify the challenges.Â
Covaxin may be more effective against UK strain: ICMR chief
The ICMR head emphasised that the scientists at ICMR have been successfully able to culture the UK strain and the efficacy of Covaxin against it will be further tested in days to come
BusinessToday.In | January 4, 2021 | Updated 16:27 IST
The head of India s premier medical research authority cited prospective effectiveness against the mutated UK strain of coronavirus as the reason behind granting emergency use authorisation to Bharat Biotech s Covaxin. India currently has 29 confirmed cases of the new COVID-19 strain that emerged first in the United Kingdom.
Talking to India Today, Dr Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), said that the scientists deliberating emergency use authorisation to various vaccines felt that Covaxin can work better in protecting against the mutated COVID-19 strain by virtue of being a whole virus vaccine.
Vaccine: DCGI panel to meet Bharat Biotech officials shortly
By IANS |
Published on
Sat, Jan 2 2021 12:36 IST |
0 Views
Vaccine: DCGI panel to meet Bharat Biotech officials shortly. Image Source: IANS News
New Delhi, Jan 2 : A committee of experts assessing the coronavirus vaccines has called Hyderabad-based Bharat Biotech for a meeting at 1.30 pm on Saturday, a day after the firm was asked to present more data on its Covaxin to get the go-ahead, a top source said.
On Friday, the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) had held that the data provided by Bharat Biotech for its coronavirus vaccine was not sufficient for the grant of approval for emergency use and sought more information.